LAG-3 is highly expressed in osteosarcoma (47).One promising combination is the use of relatlimab (anti-LAG-3) alongside nivolumab (anti-PD-1), which has shown encouraging results in melanoma and other solid tumors (48, 49). Here, LAG3 is linked to osteosarcoma.